The capital is primarily intended to advance the clinical development of the lead drug candidate, CLLTAXS01. ViferaXS is planning a randomised Phase II trial for chronic lymphocytic leukaemia. In parallel, Phase I programmes are underway for acute myeloid leukaemia and fibrolamellar carcinoma. Furthermore, the company intends to develop further preclinical programmes and expand its team. ViferaXS is a spin-off from the University of Tübingen and develops peptide-based cancer immunotherapies. The company’s proprietary technology is designed to activate cytotoxic T cells against antigens naturally present on tumour cells. Clinical data will now be crucial for the company’s further development. In addition to the lead programme moving into Phase II, ViferaXS expects results in the near future from the ongoing studies into acute myeloid leukaemia and fibrolamellar carcinoma. The funding thus provides the company with capital for several clinical programmes simultaneously and broadens the data base for the further development of its platform.
Press release from “Gesundheitsindustrie BW” dated 23 September 2026